|
Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study. |
|
|
Honoraria - Amgen; Mundipharma; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Mundipharma; Roche/Genentech |
Research Funding - Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
Consulting or Advisory Role - Celgene |
Research Funding - Novartis |
|
|
Research Funding - Gilead Sciences |
|
|
Consulting or Advisory Role - Gilead Sciences |
Speakers' Bureau - Gilead Sciences |
Research Funding - Celgene |
|
|
Honoraria - Janssen; Pfizer; Roche Pharma AG |
Consulting or Advisory Role - Gilead Sciences; Janssen; Roche Pharma AG |
Travel, Accommodations, Expenses - Pfizer; Roche Pharma AG |
|
|
Consulting or Advisory Role - Algeta ASA; OptumRx; Seagen |
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Janssen Oncology (Inst); Onyx (Inst); Pharmacyclics (Inst); Spectrum Pharmaceuticals (Inst); TG Therapeutics (Inst) |
Other Relationship - Celgene |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences; Isis Pharmaceuticals |
Travel, Accommodations, Expenses - Gilead Sciences; Novartis |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
|
|
No Relationships to Disclose |